Literature DB >> 12067860

Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance.

Gregory R Steinberg1, Michelle L Parolin, George J F Heigenhauser, David J Dyck.   

Abstract

The adipocyte-derived hormone leptin has been shown to acutely increase fatty acid (FA) oxidation and decrease esterification in resting rodent skeletal muscle. However, the effects of leptin on human skeletal muscle FA metabolism are completely unknown. In these studies, we have utilized an isolated human skeletal muscle preparation combined with the pulse-chase technique to measure FA metabolism with and without leptin in lean and obese human skeletal muscle. Under basal conditions (in the absence of leptin), muscle from the obese demonstrated significantly elevated levels of total FA uptake (+72%, P = 0.038) and enhanced rates of FA esterification into triacylglycerol (+102%, P = 0.042) compared with lean subjects. In the presence of leptin, lean muscle had elevated rates of endogenous (+103%, P = 0.01) and exogenous (+150%, P = 0.03) palmitate oxidation. When the ratio of esterification to exogenous oxidation was examined, leptin reduced this ratio (-47%, P = 0.032), demonstrating the increased partitioning of FA toward oxidation and away from storage. Contrary to these findings in lean muscle, leptin had no effect on FA metabolism in skeletal muscle of the obese. This study provides the first evidence that leptin increases FA oxidation in skeletal muscle of lean, but not obese humans, thus demonstrating the development of leptin resistance in obese human skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067860     DOI: 10.1152/ajpendo.00542.2001

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  40 in total

1.  Intramyocellular lipid accumulation is associated with permanent relocation ex vivo and in vitro of fatty acid translocase (FAT)/CD36 in obese patients.

Authors:  C Aguer; J Mercier; C Yong Wai Man; L Metz; S Bordenave; K Lambert; E Jean; L Lantier; L Bounoua; J F Brun; E Raynaud de Mauverger; F Andreelli; M Foretz; M Kitzmann
Journal:  Diabetologia       Date:  2010-03-25       Impact factor: 10.122

Review 2.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  Muscular strength, aerobic capacity, and adipocytokines in obese youth after resistance training: A pilot study.

Authors:  Sarah P Shultz; Rachana Dahiya; Gary M Leong; David S Rowlands; Andrew P Hills; Nuala M Byrne
Journal:  Australas Med J       Date:  2015-04-30

Review 4.  Counterregulation of insulin by leptin as key component of autonomic regulation of body weight.

Authors:  Katarina T Borer
Journal:  World J Diabetes       Date:  2014-10-15

5.  Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.

Authors:  Dayana B Rivadeneira; Kristin DePeaux; Yiyang Wang; Aditi Kulkarni; Tracy Tabib; Ashley V Menk; Padmavathi Sampath; Robert Lafyatis; Robert L Ferris; Saumendra N Sarkar; Stephen H Thorne; Greg M Delgoffe
Journal:  Immunity       Date:  2019-08-27       Impact factor: 31.745

Review 6.  The role of leptin in obesity and the potential for leptin replacement therapy.

Authors:  Helin Feng; Lihua Zheng; Zhangying Feng; Yaheng Zhao; Ning Zhang
Journal:  Endocrine       Date:  2012-12-29       Impact factor: 3.633

7.  gp130 receptor ligands as potential therapeutic targets for obesity.

Authors:  Mark A Febbraio
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

Review 8.  Pathogenesis of insulin resistance in skeletal muscle.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  J Biomed Biotechnol       Date:  2010-04-26

9.  Relation of leptin to left ventricular hypertrophy (from the Multi-Ethnic Study of Atherosclerosis).

Authors:  Matthew A Allison; David A Bluemke; Robyn McClelland; Mary Cushman; Michael H Criqui; Joseph F Polak; Joao A Lima
Journal:  Am J Cardiol       Date:  2013-05-24       Impact factor: 2.778

Review 10.  CNTF: a target therapeutic for obesity-related metabolic disease?

Authors:  Vance B Matthews; Mark A Febbraio
Journal:  J Mol Med (Berl)       Date:  2008-01-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.